This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
The company will be preferred business partner for VPPL in terms of sourcing and supplying key raw materials
Astec LifeSciences has reported total income of Rs. 51.70 crores during the period ended December 31, 2023
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
Subscribe To Our Newsletter & Stay Updated
